



PRESS RELEASE

November 10, 2022

CombiGene AB (publ): Nominating committee

The nominating committee has been constituted in accordance with the resolution adopted by the annual general meeting ("AGM") 2022

The AGM 2022 resolved that a nominating committee should be appointed in accordance with the following: "The nominating committee shall consist of representatives for the three largest shareholders in terms of votes as of 30 September each year. If any of these shareholders refrains from appointing a representative, the following shareholders shall, in the order of magnitude, be given the opportunity to appoint a representative until three members have been appointed. The names of the members in the nominating committee must be published by the company no later than six months prior to the coming AGM. The shareholder representative who represents the largest shareholder, shall be appointed chairman of the nominating committee, unless the nominating committee decides otherwise".

The nominating committee has been constituted in accordance with the resolution adopted by the AGM 2022. The nominating committee consists of Ivar Nordqvist, Arne Ferstad representing Myrlid AS and Marcus Isaksson representing Thoren Tillväxt AB.

The nominating committee's tasks include submitting proposals to the AGM regarding:

- Chairman of the AGM
- Election of board members
- Chairman of the board of directors
- Remuneration to the board of directors including the chairman
- Election of auditor and remuneration to the auditor
- Rules of procedure for the nominating committee

About CombiGene AB

CombiGene's vision is to offer patients affected by severe life-changing diseases opportunities for a better life through innovative gene therapies. CombiGene's business concept is to develop effective gene therapies for serious diseases that today lack adequate treatment methods. Research assets are taken in from a network of external researchers and developed further up to preclinical/clinical concept verification. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while CombiGene may drive the development and commercialization in-house for medicines aimed at limited patient populations.

The Company has signed an exclusive collaboration and licensing agreement for CombiGene's CG01 project with Spark Therapeutics.

The company is public and listed on the Nasdaq First North Growth Market and the company's Certified Advisor is FNCA Sweden AB, info@fnca.se.

For more information:

CombiGene AB (publ)

Jan Nilsson, CEO

Phone: +46 (0)704 66 31 63

jan.nilsson@combigene.com

Bert Junno, Chairman of the Board

Phone: +46(0) 70 7 77 22 09

bert.junno@combigene.com